These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 16344430

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Prevention of venous thromboembolism in internal medicine and neurology].
    Malý J, Dulícek P, Penka M, Malý R, Gumulec J.
    Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
    [Abstract] [Full Text] [Related]

  • 3. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
    Pineo GF, Hull RD.
    Eur J Med Res; 2004 Apr 30; 9(4):215-24. PubMed ID: 15210402
    [Abstract] [Full Text] [Related]

  • 4. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL.
    J Support Oncol; 2006 Mar 30; 4(3):115-20. PubMed ID: 16553136
    [Abstract] [Full Text] [Related]

  • 5. Letter 1: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Wille-Jorgensen P.
    Br J Surg; 2006 Mar 30; 93(3):374; author reply 375-6. PubMed ID: 16498577
    [No Abstract] [Full Text] [Related]

  • 6. Prevention of venous thromboembolism after neurosurgery.
    Agnelli G.
    Thromb Haemost; 1999 Aug 30; 82(2):925-30. PubMed ID: 10605805
    [No Abstract] [Full Text] [Related]

  • 7. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Agnelli G, Bergqvist D, Dahl O, Eriksson B, Rud Lassen M, Mouret P, Rosencher N.
    Br J Surg; 2006 Mar 30; 93(3):375; author reply 375-6. PubMed ID: 16498579
    [No Abstract] [Full Text] [Related]

  • 8. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Tangelder MJ, Bylock A, Held P.
    Br J Surg; 2006 Mar 30; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
    [No Abstract] [Full Text] [Related]

  • 9. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
    Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandala M, Papaldo P, Nistico C, Fabi A, Cuppone F, Gelibter A, Terzoli E, Cognetti F.
    J Clin Oncol; 2005 Oct 01; 23(28):7248-50; author reply 7250. PubMed ID: 16192623
    [No Abstract] [Full Text] [Related]

  • 10. [The risk of venous thromboembolism during air travel].
    Sanchez O.
    Rev Prat; 2007 Apr 15; 57(7):721-3. PubMed ID: 17654820
    [No Abstract] [Full Text] [Related]

  • 11. [Evidence for thrombosis prophylaxis to high-risk patients].
    Själander A, Jansson JH, Bergqvist D, Eriksson H, Svensson P.
    Lakartidningen; 2007 Apr 15; 104(20-21):1585-7. PubMed ID: 17564265
    [No Abstract] [Full Text] [Related]

  • 12. Heparin and CXCL12 dimerization.
    Altundag K, Altundag O, Atik MA.
    J Clin Oncol; 2005 Oct 01; 23(28):7248. PubMed ID: 16192624
    [No Abstract] [Full Text] [Related]

  • 13. [Practice guidelines for the prevention of venous thromboembolism in elderly patients hospitalized in subacute care and rehabilitation facilities (short text). Association for the Promotion of Hospital Angiology].
    Bosson JL, Labarère J, Barrellier MT, Belmin J, Couturier P, Le Roux P, Sevestre MA, Association pour la Promotion de l'Angiologie Hospitalière (APAH).
    J Mal Vasc; 2003 Oct 01; 28(4):209-18. PubMed ID: 14618112
    [No Abstract] [Full Text] [Related]

  • 14. Prevention of venous thromboembolism in patients.
    Hairon N.
    Nurs Times; 2003 Oct 01; 103(18):23-4. PubMed ID: 17508658
    [No Abstract] [Full Text] [Related]

  • 15. Prevention of venous thromboembolism among hospitalized medical patients.
    Goldhaber SZ, Turpie AG.
    Circulation; 2005 Jan 04; 111(1):e1-3. PubMed ID: 15630031
    [No Abstract] [Full Text] [Related]

  • 16. Selecting an agent for prophylaxis of venous thromboembolism.
    Myers J.
    Am J Health Syst Pharm; 2006 Dec 15; 63(24):2448-50. PubMed ID: 17158692
    [No Abstract] [Full Text] [Related]

  • 17. [Thromboembolisms endanger the internist patients, too: who needs heparin].
    Bischoff A.
    MMW Fortschr Med; 2006 Mar 16; 148(11):21-2. PubMed ID: 16612959
    [No Abstract] [Full Text] [Related]

  • 18. [The role of low molecular weight heparin (fragmin) in the prophylaxis and treatment of venous thromboembolism in major abdominal operations].
    Khinev S, Tsoneva D, Darfinova K, Kamenova B, Yar'mov N.
    Khirurgiia (Sofiia); 2000 Mar 16; 56(2):14-6. PubMed ID: 11484279
    [Abstract] [Full Text] [Related]

  • 19. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids.
    Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE.
    Thromb Haemost; 2007 Mar 16; 97(3):496-7. PubMed ID: 17334521
    [No Abstract] [Full Text] [Related]

  • 20. [Prevention of venous thrombosis and pulmonary artery thromboembolism in non-surgical patients: specification of indications].
    Iavelov IS.
    Ter Arkh; 2007 Mar 16; 79(9):70-9. PubMed ID: 18038592
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.